Brain damage

Lifeward Announces the Appointment of Mike Swinford to its Board of Directors

Retrieved on: 
Vendredi, avril 19, 2024

Mr. Swinford held various operational and commercial roles throughout his career leading through various business cycles from start-ups to turnarounds.

Key Points: 
  • Mr. Swinford held various operational and commercial roles throughout his career leading through various business cycles from start-ups to turnarounds.
  • “As someone who is passionate about improving healthcare access and inclusion for people with disabilities, I am excited to join the Board of Directors of Lifeward,” said Mr. Swinford.
  • This is another step to increase the direct commercialization skills and experience within our Board.
  • We are delighted to welcome Mike to the Board.”

A New Therapeutic Target for Traumatic Brain Injury

Retrieved on: 
Vendredi, avril 19, 2024

SAN FRANCISCO, April 19, 2024 /PRNewswire/ -- For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely. Not only can these injuries lead to a loss of coordination, depression, impulsivity, and difficulty concentrating, but they come with an amplified risk for developing dementia in the future.

Key Points: 
  • SAN FRANCISCO, April 19, 2024 /PRNewswire/ -- For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely.
  • "We knew that a specific blood protein, fibrin, was present in the brain after traumatic brain injury, but we didn't know until now that it plays a causative role in brain damage after injury," says Ryu, who led the study that appears in the Journal of Neuroinflammation.
  • But in this case, the traumatic brain injury itself causes the blood to leak into the brain.
  • They also produced three-dimensional imaging of a whole intact mouse brain, showing blood-brain barrier leaks and abundant fibrin in traumatic brain injury.

Are 2 mid-career AFL retirements a sign Australian athletes are taking brain health more seriously?

Retrieved on: 
Vendredi, avril 19, 2024

The 24-year-old’s seemingly sudden retirement, following Angus Brayshaw’s in February and a number of other high-profile footballers in recent years, signals a shift in how athletes view brain trauma risks in sport.

Key Points: 
  • The 24-year-old’s seemingly sudden retirement, following Angus Brayshaw’s in February and a number of other high-profile footballers in recent years, signals a shift in how athletes view brain trauma risks in sport.
  • Rather than downplaying or ignoring the potential damage being done to their health by a career filled with brain trauma, some athletes are now choosing to end their careers early.

Why do athletes risk their brains?

  • For decades, sports have fostered a win-at-all-costs culture, with a pseudo-military flavour of sacrifice and duty to one’s teammates.
  • This has given rise to athletes ignoring or downplaying injuries whenever possible to continue the game.
  • Media commentators also celebrate athletes who return to the field after sickening collisions as “courageous”, having “no fear”, or “gaining respect from teammates and opposition”.

A shift in attitude?

  • Murphy’s retirement and acknowledgement of his long-term brain health is one sign the culture of valorising injury and risk may be changing.
  • But there is other evidence of a shift.
  • Australian research shows risky attitudes and behaviours toward concussion have begun to dissipate over recent years.
  • However, a 2021 follow-up study, using the same survey in a separate group, showed significant improvements towards concussion.

Are more retirements to come?

  • In the meantime, the current group of athletes – professionals and amateurs alike – must weigh up the costs of participation in high contact games.
  • It’s in the best interests for the longevity of these sports – and the athletes we love to cheer on.
  • Alan is a non-executive unpaid director for the Concussion Legacy Foundation.
  • He has previously received funding from Erasmus+ strategic partnerships program (2019-1-IE01-KA202-051555), Sports Health Check Charity (Australia), Australian Football League, Impact Technologies Inc., and Samsung Corporation, and is remunerated for expert advice to medico-legal practices.

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Retrieved on: 
Jeudi, mars 28, 2024

HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and is further detailed in an abstract co-authored by the United States Department of Veterans Affairs (VA) San Diego Healthcare System, and the Radiology, Psychiatry and Neurosciences Departments of UC San Deigo.

Key Points: 
  • mTBI is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
  • However, the underlying pathophysiology is not completely understood, and there are few effective treatments for post-concussive symptoms (PCS).
  • The study was conducted as a randomized, double-blind, placebo-controlled clinical trial over an eight-week period, with two groups being examined: an active tACS group and a sham tACS group.
  • Mark White, CEO of Nexalin Technology, stated, "We are encouraged by the results of the clinical study, reinforcing the significant reduction in pain and other persistent symptoms of mild traumatic brain injury among veteran patients.

Association for Diagnostics & Laboratory Medicine (formerly AACC) survey of clinical labs finds that FDA's proposed laboratory developed tests rule would hinder pediatric care

Retrieved on: 
Mardi, avril 9, 2024

View the full survey results here: https://www.myadlm.org/lp/ldts-survey

Key Points: 
  • View the full survey results here: https://www.myadlm.org/lp/ldts-survey
    Laboratory developed tests are tests that clinical labs create and perform in-house to meet the needs of their local patient populations.
  • These tests are currently regulated by the Centers for Medicare & Medicaid Services (CMS) via the Clinical Laboratory Improvement Amendments (CLIA).
  • In the first week, 140 U.S. clinical labs responded to the survey, 87% of which said they perform laboratory developed tests.
  • ADLM's survey findings underscore the fact that placing these tests under additional FDA oversight would undermine care for children across the U.S."

From Reagan to Obama, presidents have left office with ‘strategic regret’ − will leaving troops in Iraq and Syria be Biden or Trump’s?

Retrieved on: 
Mardi, avril 9, 2024

U.S. presidents often leave the White House expressing “strategic regret” over perceived foreign policy failures.

Key Points: 
  • U.S. presidents often leave the White House expressing “strategic regret” over perceived foreign policy failures.
  • Lyndon Johnson was haunted by the Vietnam War.
  • Bill Clinton regretted the failed intervention in Somalia and how the “Black Hawk Down” incident contributed to his administration’s inaction over the Rwandan genocide.
  • Barack Obama said the Libyan intervention was “the worst mistake” of his presidency.

Another Beirut?

  • The Middle East has entered a volatile period.
  • The threat to U.S. personnel in the region takes the form of both the Islamic State group, which is intent on hitting Western targets, and the increased risk from a network of Iran-linked militants seeking to avenge what they see as U.S. complicity in Israel’s siege of Gaza.
  • If any mass-casualty attack on U.S. forces were to occur, the occupant of the White House would face two conditions that have left departing presidents experiencing strategic regret: the loss of American lives on their watch and the prospect of being drawn into a widening war.
  • Today’s situation in Iraq and Syria is eerily similar in many ways to the circumstances Reagan faced in Beirut, but potentially far more dangerous.
  • Like Lebanon then, U.S. troops are in Iraq and Syria for secondary, as opposed to primary, security objectives.
  • According to a recent Pentagon report, that threat remains exceedingly weak today for the United States.
  • While Reagan was unaware of the high exposure of U.S. Marines in 1983, the danger U.S. troops face today in Iraq and Syria is abundantly clear.
  • The Jordan attack aside, U.S. service members have already suffered significant injuries from missiles, including dozens of traumatic brain injuries.

Fueling hubris


Some might consider this concern about “another Beirut” overblown. After all, proxy attacks on U.S. forces in Iraq and Syria have dropped since the attack in Jordan in late January, giving the impression that deterrence is now working after big U.S. retaliatory strikes in February.

  • The 1983 Marine Corps barracks bombing was preceded a few months earlier by a smaller, yet still deadly, bombing at the U.S. embassy in Beirut.
  • In the lull that followed the embassy attack, Reagan officials didn’t pursue a strategically smart rethink of U.S. policy or consider troop reductions.
  • In short, lulls in violence like today in Iraq and Syria can fuel hubris and provide a dangerous sense of false security and a determination to stay the course.
  • As research shows, “see, I told you so” is a powerful rhetorical tool in circumstances like this.

The ghosts of history

  • But anything too large risks inviting the kind of response that could lead to lasting and devastating outcomes.
  • Imagine, for example, a scenario in which a U.S. president is provoked into striking Iran following repeated attacks by Tehran’s proxies on U.S. troops.
  • The result would be an expansion of – and further U.S. involvement in – the Middle East conflict.
  • Their experiences and the ghosts of history serve as a warning when it comes to U.S. forces in Syria and Iraq now.


Charles Walldorf received funding from Charles Koch Foundation.

Charles Walldorf is a Visiting Fellow, Defense Priorities

Rate of national measles cases highlights importance of vaccination

Retrieved on: 
Jeudi, mars 21, 2024

Nationally, the total number of measles cases has already reached the level that occurred during the entire year of 2023.

Key Points: 
  • Nationally, the total number of measles cases has already reached the level that occurred during the entire year of 2023.
  • Infants as young as 6 months can receive the first dose if traveling to areas where the measles infection rate is high.
  • Herd immunity, achieved through a measles vaccination rate of 95% or more, is crucial for preventing disease outbreaks in the community and protecting vulnerable populations who cannot receive vaccines.
  • The measles vaccine, given as part of the MMR (measles, mumps and rubella) vaccine, is extremely effective, giving those vaccinated with just one dose 93% protection against measles infection.

CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders

Retrieved on: 
Jeudi, mars 21, 2024

“Most importantly, the clinical development of CMP-CPS-001 is a step toward potentially bringing a new, disease-modifying treatment to individuals living with UCDs.

Key Points: 
  • “Most importantly, the clinical development of CMP-CPS-001 is a step toward potentially bringing a new, disease-modifying treatment to individuals living with UCDs.
  • People with urea cycle disorders accumulate excessive ammonia in their blood, which may cause irreversible brain damage, disability, and seizures, and may be fatal.
  • CMP-CPS-001 targets carbamoyl phosphate synthetase 1 (CPS1), a key enzyme that catalyzes the first step of the urea cycle.
  • For more information about the Phase 1 clinical study of CMP-CPS-001, please visit clinicaltrials.gov ( NCT06247670 ).

Bipartisan Legislation Makes Patient Safety a National Priority

Retrieved on: 
Lundi, mars 11, 2024

This landmark bipartisan legislation, announced during Patient Safety Awareness Week, is a critical step to improve safety for patients and healthcare providers by adopting patient safety solutions.

Key Points: 
  • This landmark bipartisan legislation, announced during Patient Safety Awareness Week, is a critical step to improve safety for patients and healthcare providers by adopting patient safety solutions.
  • The National Patient Safety Board Act would create a National Patient Safety Board (NPSB), a data-driven, nonpunitive, collaborative, independent research and development team housed within the Department of Health and Human Services to address safety in health care.
  • The establishment of a National Patient Safety Board would enable a collaborative, evidence-based and scalable solution to optimize patient safety across our country’s healthcare system,” said Peter WT Pisters, MD, president of The University of Texas MD Anderson Cancer Center.
  • “Patient safety is our number one priority for every decision we make as a health system.

Psilera Welcomes Biopharma Executive Dr. Magali Haas to its Board of Directors

Retrieved on: 
Mardi, mars 26, 2024

TAMPA, Fla., March 26, 2024 /PRNewswire/ -- Psilera, a leading biotechnology company developing groundbreaking therapies for hard-to-treat neurological disorders, is pleased to announce the appointment of Magali Haas, M.D., Ph.D., to its esteemed Board of Directors.

Key Points: 
  • TAMPA, Fla., March 26, 2024 /PRNewswire/ -- Psilera, a leading biotechnology company developing groundbreaking therapies for hard-to-treat neurological disorders, is pleased to announce the appointment of Magali Haas, M.D., Ph.D., to its esteemed Board of Directors.
  • Psilera adds key player to Board to further advance their next-generation neurological drug development.
  • "We are thrilled to welcome Magali as an independent member of our Board of Directors," said Dr. Chris Witowski, CEO of Psilera.
  • "Joining the board of Psilera provides a thrilling opportunity to be at the forefront of brain health research," said Dr. Haas.